| Audience | Patients, clinicians, healthcare providers, researchers, and policy analysts. |
| Primary Topic | Clinical study review: Evaluating Palliative Pain Strategies in Older Adu. |
| Source | Read the full source |
Evaluating Palliative Pain Strategies in Older Adults Across Clinical Evidence
This scoping review maps 117 studies on palliative pain management in older adults, revealing heavy research emphasis on cancer and opioids while highlighting significant gaps in non-cancer populations and high-quality data.
| Post Type | Physician-Guided Clinical Science Deep Dive |
| Primary Source | Ageing research reviews |
| Publication Date | 2026Oct18 |
| Evidence Level | Journal Article, Review |
| Focus Area | Evaluating Palliative Pain Strategies in Older Adults Across |
| Lead Authors | Mélanie Bérubé, Sandrine Linsotan, Lynn Gauthier, Bradley Godwin et al. |
| DOI | 10.1016/j.arr.2026.103423 |
| PMID | PMID: 42893776 |
Mainstream Media Claim: Modern medicine has perfected palliative pain care for the elderly through advanced protocols.
Primary Journal Data: 68% of 117 studies yielded moderate-to-low level evidence, mostly focused on young-old cancer patients.
Dr. Caplan’s Clinical Verdict: Palliative pain care relies heavily on low-quality evidence and extrapolation from younger cancer populations.
Study Overview: With the aging population, the demand for palliative care is expected to increase. Pain management is a critical component of palliative care with unique considerations for older patients. The aim of this scoping review was to map the nature and extent of the evidence on pain management strategies in this population. We searched databases for peer-reviewed studies and grey literature on pain management in older adults receiving palliative care. Strategies were classified as opioid analgesics, non-opioid medications, procedural, non-pharmacological, educational, and multifaceted interventions. Frequencies and proportions were used to describe the strategies, reported improvements, and levels of evidence. We included 117 studies. Most focused on cancer populations (82/117, 71%), and the majority of participants (98/114, 86%) were aged 65-74 years on average. Overall, 68% of the studies yielded moderate to low level of evidence. Opioids and multifaceted interventions were the most frequently evaluated strategies, each examined in 32% (37/117) of studies. Across both high- and moderate/low-evidence studies, pain reduction was most consistently reported for procedural interventions (3/3, 100%; 3/3, 100%), opioids (3/5, 60%; 25/32, 78%), and multifaceted interventions (4/9, 44%; 20/23, 87%). Favourable findings were most often reported for combinations of opioids, opioids for breakthrough pain, nerve blocks or local anesthesia, cannabis, music or massage therapy, exercise, and biopsychosocial or care organization interventions. This review mapped pain management strategies for older adults in palliative care, identified key evidence gaps, particularly among oldest-old individuals and those with non-cancer conditions, and highlighted the need for stronger research.
Primary Source & Scope: Published in Ageing research reviews (2026Oct18) conducted by Mélanie Bérubé, Sandrine Linsotan, Lynn Gauthier, Bradley Godwin et al.. Primary Source Link | Primary Record: DOI: 10.1016/j.arr.2026.103423 | PMID: 42893776
Palliative medicine has long faced a scarcity of high-level clinical trial data, largely due to ethical and logistical challenges in studying terminally ill populations. Historically, pain management guidelines for older adults have been extrapolated from younger, healthier cohorts, leading to frequent overreliance on single-agent opioid escalation.
In recent years, the growing interest in multimodal and integrative pain care has highlighted the potential of non-opioid strategies, including cannabinoid therapies, regional nerve blocks, and mind-body interventions. As global demographics shift toward an older population with complex multimorbidity, research efforts are increasingly focusing on individualized, low-toxicity regimens that prioritize functional quality of life over rigid pharmacological escalation.
Palliative pain management for older adults sits at the intersection of complex pharmacology, organ fragility, and quality-of-life goals. The scoping review highlights a stark reality: despite widespread clinical reliance on opioids and multifaceted care, the foundational evidence supporting these interventions is surprisingly modest. With 68 percent of the 117 reviewed studies offering moderate-to-low quality evidence, healthcare providers are frequently forced to navigate patient care using extrapolated findings rather than high-grade, population-specific data.
The narrow focus on cancer populations aged 65 to 74 leaves significant knowledge gaps regarding the oldest-old population and those suffering from non-oncological terminal illnesses, such as advanced heart failure, dementia, or chronic kidney disease. These patients often experience distinct pain phenotypes and altered drug kinetics that render standard opioid regimens unpredictable or harmful. Integrating lower-risk adjuvant strategies, including procedural nerve blocks, specialized exercise, and cannabinoid formulations, offers a pragmatic pathway to reduce total medication burden while addressing complex pain dynamics.
Bridging these evidence gaps requires a systemic shift toward inclusive pragmatic research that reflects real-world clinical demographics. Clinical teams must remain cautious when applying high-dose opioid strategies to frail elders, prioritizing multimodal models that combine targeted pharmacology with integrative therapies. Establishing protocols tailored specifically to non-cancer palliative care will ultimately ensure safer, more effective pain relief for an aging global population.
How to Interpret This Clinical Study
Navigating biomedical publications regarding Pain Management Strategies for Older Adults i requires reviewing study methodology and patient eligibility.
Three Rules for Critical Reading
Critical Rule
Recognize that published palliative pain data largely reflect young-old cancer populations rather than the entire elderly demographic.
Critical Rule
Evaluate multimodal interventions, including procedural and integrative options, to minimize relying solely on high-dose opioids.
Critical Rule
Account for age-related pharmacokinetic changes when designing individualized symptom control plans.
CED Perspective Lens: Eight Clinical Viewpoints
Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives
Clinical Evidence Synthesis
A comprehensive scoping review evaluated 117 studies examining pain management strategies in older adults receiving palliative care. Cancer populations represented 71 percent of included research, while 86 percent of subjects were between 65 and 74 years old. Opioids and multifaceted care models were evaluated most frequently, each appearing in 32 percent of the literature.
Methodological strength was overwhelmingly moderate to low, comprising 68 percent of all analyzed studies. Procedural interventions, opioids, and multifaceted care showed the most consistent pain reduction, with integrative additions like cannabis and nerve blocks offering favorable clinical signals.
Patient Communication
Older patients and family caregivers frequently navigate fragmented care when seeking relief from severe or persistent pain. Open dialogue about treatment goals helps align expectation management with clinical reality. Clinicians should outline both pharmacological and non-pharmacological choices clearly, addressing concerns regarding sedation, cognitive changes, and dependency.
Including non-pharmacological strategies like massage, music therapy, or mild physical exercise alongside conventional analgesics helps patients regain a sense of agency. Setting realistic goals focused on functional comfort rather than total pain elimination improves satisfaction and clinical outcomes.
Dosing & Formulations
Pharmacokinetics in older adults mandate precise dosage titration due to age-related declines in hepatic clearance and renal filtration. Standard opioid regimens often carry elevated risk for confusion, constipation, and respiratory depression in elderly individuals.
Combining low-dose opioids with targeted non-pharmacological interventions or cannabinoid-based therapies offers a strategy to lower total opioid burden. Micro-titration allows clinicians to observe therapeutic response while minimizing adverse reactions, particularly when addressing breakthrough pain. In everyday practice, evaluating dosing considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Safety & Side Effect Profile
Safety considerations dominate clinical decision-making when prescribing analgesics for older adults in palliative care. Polypharmacy increases the likelihood of adverse drug interactions, drug-disease interactions, and metabolic complications.
Non-opioid analgesics and adjuvant therapies require careful monitoring for renal impairment and cardiovascular risks. Incorporating non-pharmacological modalities like nerve blocks or physical therapies provides effective symptom relief without compounding systemic toxicity. In everyday practice, evaluating safety considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Regulatory & Policy Dynamics
Health policies regarding palliative care frequently fail to reflect the clinical realities of an aging society. Access to comprehensive multidisciplinary pain management remains restricted by reimbursement models that favor acute pharmacological prescriptions over long-term integrative care.
Regulatory frameworks surrounding controlled substances and medical cannabis create institutional barriers for palliative programs. Streamlining institutional guidelines enables clinical teams to deploy multimodal pain strategies without navigating prohibitive administrative hurdles. In everyday practice, evaluating regulatory considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Mechanisms & Physiology
Pain perception in older adults involves altered nociceptive processing, central sensitization, and structural nerve changes. Age-related changes in receptor density alter responsiveness to conventional opioid analgesics.
Multimodal strategies target distinct physiological pathways simultaneously. Combining receptor-targeted medications with therapies that modulate endocannabinoid signaling or local nerve transmission provides synergistic analgesia, reducing dependency on single high-dose drug classes. In everyday practice, evaluating mechanisms considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Research Limitations
The existing literature suffers from significant demographic imbalances, with 71 percent of studies focused on cancer pain and 86 percent restricted to younger-old cohorts. Data regarding individuals aged 75 and older remain sparse across clinical settings.
High-grade randomized controlled trials represent a small minority of published research. This lack of data limits the generalizability of findings to non-cancer palliative care patients with complex multimorbidity. In everyday practice, evaluating limits considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Future Outlook
Future research must prioritize inclusive clinical trials that specifically enroll individuals over 75 years of age with non-cancer terminal illnesses. Studying real-world pragmatic interventions will better reflect true clinical practice.
Investigating optimized combinations of opioids, nerve interventions, and cannabinoid therapies will clarify precise synergy metrics. Standardization of outcome measures will accelerate the adoption of effective integrative care protocols. In everyday practice, evaluating outlook considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is the main finding of this scoping review on palliative pain management?
The review analyzed 117 studies and found that while opioids and multifaceted interventions are most frequently studied, 68% of the evidence is moderate-to-low quality and heavily focused on cancer patients aged 65 to 74.
Why is there a gap in evidence for patients older than 75?
Most included studies focused on younger-old adults (65-74 years), leaving a lack of clinical trial data specifically evaluating safety, dosing, and efficacy in the oldest-old population.
Which pain management strategies showed the most consistent pain reduction?
Procedural interventions (such as nerve blocks), opioids, and multifaceted care models reported the most consistent pain reduction across varying evidence levels.
What role do non-opioid therapies play in palliative care for older adults?
Non-opioid strategies, including exercise, music, massage, and cannabis, demonstrated favorable outcomes as part of multifaceted plans, helping reduce overreliance on high-dose opioids.
How does cancer status affect the evidence available for palliative pain treatment?
Cancer populations represented 71% of all reviewed studies, meaning that non-cancer palliative conditions, such as heart failure or dementia, are significantly underrepresented in current research.
What are multifaceted interventions in palliative care?
Multifaceted interventions combine several treatment types, such as medical management, physical therapies, psychological support, and organizational care coordination, to address complex pain.
How does aging alter response to pain medications?
Aging reduces liver clearance and kidney excretion, which increases drug sensitivity, risk of toxicity, sedation, and cognitive side effects from conventional pain medications.
What is the evidence for medical cannabis in palliative pain care according to this review?
Cannabis was identified as an adjuvant strategy yielding favorable clinical outcomes when combined with standard care, though further high-quality trials are needed.
Why are high-quality randomized trials rare in palliative care?
Conducting trial research in terminally ill, frail populations poses substantial ethical challenges, recruitment difficulties, and high attrition rates.
How should clinicians approach pain care for older non-cancer palliative patients?
Clinicians should start with low doses, titrate slowly, and combine non-pharmacological and procedural options to achieve pain relief without excessive organ stress or polypharmacy.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
